- Molecular NameEflornithine
- SynonymNA
- Weight182.17
- Drugbank_IDN/A
- ACS_NO67037-37-0
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-3.03
- pkaN/A
- LogD (pH=7, predicted)-3.05
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.06
- LogSw (predicted, AB/LogsW2.0)299.71
- Sw (mg/ml) (predicted, ACD/Labs)12.37
- No.of HBond Donors5
- No.of HBond Acceptors4
- No.of Rotatable Bonds5
- TPSA89.34
- StatusN/A
- AdministrationIntravenous (discontinued), Dermal
- PharmacologyA drug manufactured by Sanofi-Aventis that has various uses. It was initially developed for cancer treatment, but, while having little use in treating malignancies, it was found to be highly effective in African trypanosomiasis (sleeping sickness), especially the West African form (Trypanosoma brucei gambiense).
- Absorption_value55.0
- Absorption (description)Eflornithine is absorbed (approx. 60%) after oral administration
- Caco_2N/A
- Bioavailability55.0
- Protein bindingN/A
- Volume of distribution (VD)0.33 to 0.37 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmEflornithine is not known to be metabolized and is primarily excreted unchanged in the urine.
- Half life3~4 h
- Excretion>80% of the dose is excreted in urine, 40 to 45% of which remains unchanged. The drug is distributed into central spinal fluid.
- Urinary ExcretionN/A
- CleranceTotal body clearance, 1.17 mL/min/kg.
- ToxicityThe most frequently reported adverse events are acne, Pseudofolliculitis Barba, and stingin skin.[
- LD50 (rat)N/A
- LD50 (mouse)N/A